Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
US Army
Argus Health
Fish and Richardson
US Department of Justice
Citi
Teva
Merck
McKesson

Generated: May 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,977,376

« Back to Dashboard

Which drugs does patent 7,977,376 protect, and when does it expire?

Patent 7,977,376 protects PATANASE and is included in one NDA.

Protection for PATANASE has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-eight patent family members in twenty countries.
Summary for Patent: 7,977,376
Title:Olopatadine formulations for topical nasal administration
Abstract: Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the nose are disclosed. The aqueous formulations contain approximately 0.6% (w/v) of olopatadine.
Inventor(s): Singh; Onkar N. (Arlington, TX), Wall; G. Michael (Fort Worth, TX), Jani; Rajni (Fort Worth, TX), Chowhan; Masood A. (Arlington, TX), Han; Wesley Wehsin (Arlington, TX)
Assignee: Novartis AG (Basal, CH)
Application Number:11/703,373
Patent Claim Types:
see list of patent claims
Composition; Formulation;

Drugs Protected by US Patent 7,977,376

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis Pharms Corp PATANASE olopatadine hydrochloride SPRAY, METERED;NASAL 021861-001 Apr 15, 2008 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,977,376

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,399,508 Olopatadine formulations for topical nasal administration ➤ Try a Free Trial
6,995,186 Olopatadine formulations for topical administration ➤ Try a Free Trial
7,402,609 Olopatadine formulations for topical administration ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,977,376

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 034619 ➤ Try a Free Trial
Austria 295149 ➤ Try a Free Trial
Australia 2002310461 ➤ Try a Free Trial
Brazil 0210707 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Daiichi Sankyo
Moodys
Julphar
Farmers Insurance
Chubb
Mallinckrodt
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.